Kinase inhibitor

Epidermal growth factor receptor inhibitors ( EGFRi ), EGFR tyrosine kinase inhibitors ( TKI ) and anti‐EGFR antibodies commonly develop...


The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...


The FDA ( Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with...


The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...


Dacomitinib is an irreversible, pan-epidermal growth factor receptor ( HER ) inhibitor. The goal of a study was to evaluate the...


The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment...


Approximately 10% of EGFR mutants harbor uncommon mutations, which represent a heterogeneous group of rare molecular alterations within exons 18-21...


Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta...


Treatment with Nazartinib ( EGF816 ), a third generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (...


A combination of the immune checkpoint blocker, Avelumab ( Bavencio ), plus the tyrosine kinase inhibitor ( TKI ),...


The FDA ( U.S. Food and Drug Administration ) has approved Larotrectinib ( Vitrakvi ), the first oral TRK inhibitor. The...


Activation of FGFR signaling is involved in a variety of malignancies including advanced urothelial cancer. Rogaratinib is an oral pan-FGFR...


Clinical data for Larotrectinib ( Vitrakvi ), an oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with...


Cabozantinib ( Cabometyx ) is an oral multitargeted tyrosine kinase inhibitor ( TKI ) that potently inhibits MET and AXL,...


Tofacitinib ( Xeljanz ) is an oral, small molecule Janus kinase [ JAK ] inhibitor that is being investigated for...


The FDA ( US Food and Drug Administration ) has approved Kisqali ( Ribociclib ) for women with hormone-receptor positive,...


Researchers at Columbia University Medical Center ( CUMC ) have discovered that the fusion of two adjacent genes can...


The FDA ( U.S. Food and Drug Administration ) has approved Nerlynx ( Neratinib ) for the extended adjuvant treatment...